Anavex Life Sciences Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Anavex Life Scienceshan disminuido a un ritmo medio anual de -20.6%, mientras que en el sector Biotechs los beneficios se situaron en growing a un ritmo anual de 17.4%.
Información clave
-18.4%
Tasa de crecimiento de los beneficios
-6.1%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera | -31.8% |
Margen neto | n/a |
Última actualización de beneficios | 31 Dec 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Anavex shares up 65% in morning trading continuing hot streak
Feb 04Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum
Jan 05Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Jan 01Anavex Life Sciences EPS beats by $0.06
Dec 28Anavex's blarcamesine successful in mid-stage rett syndrome study
Dec 15Additional U.S. patents for Anavex Life Sciences' blarcamesine
Nov 30Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Anavex Life Sciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 0 | -43 | 11 | 38 |
30 Sep 23 | 0 | -48 | 12 | 41 |
30 Jun 23 | 0 | -52 | 13 | 42 |
31 Mar 23 | 0 | -53 | 13 | 41 |
31 Dec 22 | 0 | -50 | 13 | 38 |
30 Sep 22 | 0 | -48 | 13 | 35 |
30 Jun 22 | 0 | -45 | 12 | 32 |
31 Mar 22 | 0 | -43 | 11 | 32 |
31 Dec 21 | 0 | -41 | 11 | 29 |
30 Sep 21 | 0 | -38 | 9 | 28 |
30 Jun 21 | 0 | -32 | 8 | 24 |
31 Mar 21 | 0 | -28 | 7 | 22 |
31 Dec 20 | 0 | -28 | 6 | 22 |
30 Sep 20 | 0 | -26 | 6 | 21 |
30 Jun 20 | 0 | -26 | 6 | 20 |
31 Mar 20 | 0 | -26 | 6 | 20 |
31 Dec 19 | 0 | -26 | 7 | 20 |
30 Sep 19 | 0 | -26 | 7 | 20 |
30 Jun 19 | 0 | -26 | 7 | 20 |
31 Mar 19 | 0 | -23 | 7 | 16 |
31 Dec 18 | 0 | -20 | 7 | 14 |
30 Sep 18 | 0 | -17 | 6 | 11 |
30 Jun 18 | 0 | -17 | 6 | 11 |
31 Mar 18 | 0 | -18 | 6 | 12 |
31 Dec 17 | 0 | -14 | 5 | 9 |
30 Sep 17 | 0 | -13 | 5 | 9 |
30 Jun 17 | 0 | -15 | 7 | 8 |
31 Mar 17 | 0 | -13 | 7 | 7 |
31 Dec 16 | 0 | -14 | 6 | 8 |
30 Sep 16 | 0 | -15 | 8 | 7 |
30 Jun 16 | 0 | -14 | 8 | 4 |
31 Mar 16 | 0 | -16 | 8 | 4 |
31 Dec 15 | 0 | -15 | 8 | 3 |
30 Sep 15 | 0 | -12 | 5 | 2 |
30 Jun 15 | 0 | -15 | 2 | 2 |
31 Mar 15 | 0 | -12 | 2 | 1 |
31 Dec 14 | 0 | -11 | 2 | 1 |
30 Sep 14 | 0 | -10 | 2 | 1 |
30 Jun 14 | 0 | -5 | 3 | 0 |
31 Mar 14 | 0 | -4 | 3 | 0 |
31 Dec 13 | 0 | -3 | 2 | 0 |
30 Sep 13 | 0 | -4 | 2 | 0 |
Ingresos de calidad: AVXL actualmente no es rentable.
Margen de beneficios creciente: AVXL actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: AVXL no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 20.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de AVXL en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: AVXL no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Rentabilidad financiera
Alta ROE: AVXL tiene un Rendimiento de los fondos propios negativo (-33.49%), ya que actualmente no es rentable.